PTC Therapeutics, Inc. appointed Jessica Chutter to its board of directors effective March 24, 2026, filling a vacancy as a Class I director with term expiring at the 2026 annual stockholder meeting. Ms. Chutter, with over 40 years at Morgan Stanley including as Chair of Biotechnology Investment Banking, will receive compensation per the outside director policy including a $50,000 annual retainer and specified equity grants.
Key takeaways
Jessica Chutter appointed to Board effective March 24, 2026, as Class I director.
Over 40 years experience at Morgan Stanley, including Vice Chair of Healthcare Investment Banking (2020-February 2026) and Chair of Biotechnology Investment Banking (2010-2026).
Initial equity grant: 3,475 stock options (vesting monthly over 36 months) and 4,000 RSUs (vesting in three equal annual installments from March 24, 2027).
Pro-rated 2026 annual equity grant: 2,896 stock options (vesting in ten monthly installments from April 2, 2026) and 3,333 RSUs (1,000 on June 2, 2026; 2,333 on January 2, 2027).